重新利用铂类化疗药物用于胶质母细胞瘤的多模式治疗。
Repurposing platinum-based chemotherapies for multi-modal treatment of glioblastoma.
作者信息
Roberts Nathan B, Wadajkar Aniket S, Winkles Jeffrey A, Davila Eduardo, Kim Anthony J, Woodworth Graeme F
机构信息
Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD, USA; Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA; Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, USA; Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD, USA.
出版信息
Oncoimmunology. 2016 Aug 19;5(9):e1208876. doi: 10.1080/2162402X.2016.1208876. eCollection 2016.
Glioblastoma (GBM) is a fatal brain cancer for which new treatment options are sorely needed. Platinum-based drugs have been investigated extensively for GBM treatment but few have shown significant efficacy without major central nervous system (CNS) and systemic toxicities. The relative success of platinum drugs for treatment of non-CNS cancers indicates great therapeutic potential when effectively delivered to the tumor region(s). New insights into the broad anticancer effects of platinum drugs, particularly immunomodulatory effects, and innovative delivery strategies that can maximize these multi-modal effects and minimize toxicities may promote the re-purposing of this chemotherapeutic drug class for GBM treatment.
胶质母细胞瘤（GBM）是一种致命的脑癌，迫切需要新的治疗方案。基于铂的药物已被广泛研究用于GBM治疗，但很少有药物在没有严重中枢神经系统（CNS）和全身毒性的情况下显示出显著疗效。铂类药物在治疗非CNS癌症方面的相对成功表明，当有效递送至肿瘤区域时具有巨大的治疗潜力。对铂类药物广泛抗癌作用的新见解，特别是免疫调节作用，以及能够最大化这些多模式效应并最小化毒性的创新递送策略，可能会促进这类化疗药物重新用于GBM治疗。
Zotero 插件